<DOC>
	<DOCNO>NCT01752933</DOCNO>
	<brief_summary>A Phase 2 open-label , single-arm , non-randomized study treatment advance hepatocellular carcinoma ( HCC ) patient fail prior treatment sorafenib use Simon 's 2-stage design . A set minimum number patient must demonstrate disease control 16 week proceed Stage 2 . At Stage 2 , set number patient must disease control 16 week declare SGI-110 interest treatment advance HCC failure prior sorafenib .</brief_summary>
	<brief_title>SGI-110 Treatment Advanced Hepatocellular Carcinoma ( HCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . 18 year age old 2 . Histological cytological confirm hepatocellular carcinoma advance stage disease 3 . Received prior sorafenib treatment , show evidence disease progression , define Investigator verify radiologic progression , intolerance prior systemic therapy , define clinically significant adverse event persist despite one dose reduction interruption 4 . ECOG performance status 01 5 . Acceptable organ function 6 . Signed approve informed consent 1 . Known hypersensitivity SGI110 2 . Adequate washout prior radiation , chemotherapy locoregional therapy 3 . Abnormal leave ventricular ejection fraction 4 . Uncontrolled ischemic heart disease history congestive cardiac failure 5 . Known brain metastasis 6 . Clinically evident ascites 7 . ChildPugh C cirrhosis ChildPugh B cirrhosis 7 point 8 . Prior malignancy , except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , nonmetastatic prostate cancer normal PSA cancer subject disease free least three year 9 . Known history human immunodeficiency virus ( HIV )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>